Summary
12.07 0.07(0.58%)07/01/2024
Liquidia Corp (LQDA)
Liquidia Corp (LQDA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.91 | -4.18 | -16.77 | -19.14 | 4.67 | 54.24 | 51.62 | 8.73 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.07 | |
| Open | 12.05 | |
| High | 12.27 | |
| Low | 11.85 | |
| Volume | 467,141 | |
| Change | 0.11 | |
| Change % | 0.91 | |
| Avg Volume (20 Days) | 653,425 | |
| Volume/Avg Volume (20 Days) Ratio | 0.71 | |
| 52 Week Range | 5.71 - 16.99 | |
| Price vs 52 Week High | -28.96% | |
| Price vs 52 Week Low | 111.37% | |
| Range | 0.16 | |
| Gap Up/Down | -0.35 | |
Fundamentals | ||
| Market Capitalization (Mln) | 920 | |
| EBIDTA | -36,538,372 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 6.75 | |
| Book Value | 1.4040 | |
| Earnings Per Share | -0.8350 | |
| EPS Estimate Current Quarter | -0.1200 | |
| EPS Estimate Next Quarter | -0.1200 | |
| EPS Estimate Current Year | -0.5900 | |
| EPS Estimate Next Year | -0.6200 | |
| Diluted EPS (TTM) | -0.8350 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -2.8665 | |
| Return on asset (TTM) | -0.1943 | |
| Return on equity (TTM) | -0.5657 | |
| Revenue TTM | 10,377,966 | |
| Revenue per share TTM | 0.2220 | |
| Quarterly Revenue Growth (YOY) | -1.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 501,916 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.0632 | |
| Revenue Enterprise Value | 16.9320 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 51,978,000 | |
| Shares Float | 34,662,046 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 19.98 | |
| Institutions (%) | 39.47 | |
06/18 08:42 EST - globenewswire.com
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposia of Pulmonary Hypertension (WSPH) taking place June 29 to July 1, 2024, in Barcelona, Spain. The posters outlined below address the clinical investigations of Liquidia's investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension sustained-release formulation to treat people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the company will present seven posters related to its product pipeline at the 7th World Symposia of Pulmonary Hypertension (WSPH) taking place June 29 to July 1, 2024, in Barcelona, Spain. The posters outlined below address the clinical investigations of Liquidia's investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension sustained-release formulation to treat people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
06/03 10:45 EST - investors.com
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.
05/14 11:05 EST - seekingalpha.com
Liquidia Corporation (LQDA) Q1 2024 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Dr. Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and CFO Dr. Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Jason Gerberry - Bank of America Serge Belanger - Needham Julian Harrison - BTIG Kambiz Yazdi - Jefferies Matt Kaplan - Ladenburg Thalmann Operator Good morning. And welcome everyone to the Liquidia Corporation First Quarter 2024 Financial Results and Corporate Update Conference Call.
Liquidia Corporation (LQDA) Q1 2024 Earnings Call Transcript
Liquidia Corporation (NASDAQ:LQDA ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Jason Adair - Chief Business Officer Dr. Roger Jeffs - Chief Executive Officer Michael Kaseta - Chief Operating Officer and CFO Dr. Rajeev Saggar - Chief Medical Officer Scott Moomaw - Chief Commercial Officer Rusty Schundler - General Counsel Conference Call Participants Jason Gerberry - Bank of America Serge Belanger - Needham Julian Harrison - BTIG Kambiz Yazdi - Jefferies Matt Kaplan - Ladenburg Thalmann Operator Good morning. And welcome everyone to the Liquidia Corporation First Quarter 2024 Financial Results and Corporate Update Conference Call.
05/14 10:35 EST - zacks.com
Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
Liquidia Technologies (LQDA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
Liquidia Technologies (LQDA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
05/13 17:43 EST - globenewswire.com
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024.
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024.
05/10 08:00 EST - globenewswire.com
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data at the American Thoracic Society (ATS) 2024 International Conference.
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data at the American Thoracic Society (ATS) 2024 International Conference.
04/25 11:06 EST - zacks.com
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
Liquidia Technologies (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
Liquidia Technologies (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/02 09:00 EST - globenewswire.com
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, beginning at 1:30 p.m. Eastern Time.
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, beginning at 1:30 p.m. Eastern Time.
04/01 06:00 EST - globenewswire.com
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
MORRISVILLE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on March 28, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) has set aside the injunction that was issued in August 2022 in the lawsuit filed by United Therapeutics (UTHR) in Case No. 1:20-cv-00755-RGA (the Original Hatch-Waxman Litigation). As a result, the U.S. Food and Drug Administration (FDA) is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
MORRISVILLE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on March 28, Judge Andrews of the U.S. District Court for the District of Delaware (District Court) has set aside the injunction that was issued in August 2022 in the lawsuit filed by United Therapeutics (UTHR) in Case No. 1:20-cv-00755-RGA (the Original Hatch-Waxman Litigation). As a result, the U.S. Food and Drug Administration (FDA) is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder.
03/13 14:40 EST - seekingalpha.com
Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript
Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript
Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript
Liquidia Corporation (LQDA) Q4 2023 Earnings Call Transcript
03/13 08:11 EST - zacks.com
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.09 per share a year ago.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.09 per share a year ago.
03/13 06:00 EST - globenewswire.com
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the 2023 financial results and provide a corporate update.
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the full year ended December 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the 2023 financial results and provide a corporate update.
03/06 06:44 EST - headlinesoftoday.com
Liquidia Corporation to Report Full Year 2023 Financial
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on …
Liquidia Corporation to Report Full Year 2023 Financial
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on …
03/06 06:30 EST - globenewswire.com
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
02/21 06:08 EST - reuters.com
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application
United Therapeutics said on Wednesday it has commenced litigation with the U.S. FDA for allowing an application for a drug by Liquidia Corp to treat a type of blood vessel disorder.
United Therapeutics starts litigation with FDA for allowing Liquidia's drug application
United Therapeutics said on Wednesday it has commenced litigation with the U.S. FDA for allowing an application for a drug by Liquidia Corp to treat a type of blood vessel disorder.
02/12 22:49 EST - seekingalpha.com
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a sustained-release inhaled Treprostinil product, which could compete with United Therapeutics' revenue products.
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
Liquidia's stock has increased in value by 209.32% since June 2022. Liquidia's PAH drug, Yutrepia, is expected to launch in the first or second quarter of 2024, potentially leading to profitability. Liquidia has gained a major partnership for a sustained-release inhaled Treprostinil product, which could compete with United Therapeutics' revenue products.
01/30 06:30 EST - globenewswire.com
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 through February 3, 2024, in London, England. L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily to treat patients diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
MORRISVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31 through February 3, 2024, in London, England. L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily to treat patients diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
01/29 10:56 EST - zacks.com
Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 71.4% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 71.4% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
01/25 06:17 EST - reuters.com
US FDA extends review for Liquidia's inhaled blood pressure drug
The U.S. Food and Drug Administration extended the review of Liquidia Corp's drug for the treatment of a progressive blood vessel disorder related to a lung condition, the company said on Thursday.
US FDA extends review for Liquidia's inhaled blood pressure drug
The U.S. Food and Drug Administration extended the review of Liquidia Corp's drug for the treatment of a progressive blood vessel disorder related to a lung condition, the company said on Thursday.
01/25 06:00 EST - globenewswire.com
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA. Accordingly, the FDA is not able to issue an action letter in time to meet the previously issued Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024, and their review remains ongoing. The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date.
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
MORRISVILLE, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA informed the Company that it is confirming the process for adding the PH-ILD indication as an amendment to the NDA for YUTREPIA. Accordingly, the FDA is not able to issue an action letter in time to meet the previously issued Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024, and their review remains ongoing. The FDA did not request any additional clinical data to support the NDA and did not issue a new PDUFA goal date.